Screener
Generate Biomedicines, Inc. GENB Common Stock
Common Stock at other companies
Other financials
Where this comes from
Reported directly by Generate Biomedicines, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CommonStockValue.
The source filing: Generate Biomedicines, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 6:01 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-336437
| Line item | As of June 30, 2026 | As of December 31, 2025 |
|---|---|---|
| Convertible preferred stock | — | 811,826 |
| Non-controlling interest | — | (7,232) |
| Stockholders’ equity (deficit): | ||
| Common stock, par value $0.001; 500,000,000 and 200,456,735 shares authorized as of June 30, 2026 and December 31, 2025 respectively; 128,269,428 and 33,116,957 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively | 128 | 33 |
| Additional paid-in capital | 1,261,040 | 60,189 |
| Accumulated other comprehensive (loss) income | (129) | 106 |
| Accumulated deficit | (804,994) | (676,293) |
| Total stockholders’ equity (deficit) | 456,045 | (615,965) |
Item 1. Financial Statements (Unaudited).
FAQ
- What is Generate Biomedicines, Inc.'s common stock?
- Generate Biomedicines, Inc. (GENB) reported common stock of $128K in Q2 2026.
- What does common stock mean?
- The par value of all common shares issued and outstanding, typically a nominal amount ($0.01 or $0.001 per share).
Ask your AI about Generate Biomedicines, Inc.'s common stock.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude